← The Wire
ZBIONasdaq
Zenas BioPharma, Inc.
Pharmaceutical Preparations · DE · CIK 1953926
Develops and commercializes immunology-based therapies for autoimmune diseases, focusing on obexelimab
red 8-K · 90d
$1.25B
Market cap
$25.55
Last close
-1.2%
1D
+22.8%
5D
1.7M
Volume
Price · last 39 sessions+18.5%
May 4L $16.91 · H $25.87Jun 29
41
Total filings
May 13, 2026
Last filing
12/31
Fiscal year end
10-Q10-QMay 13, 20268-KExecutive Change · Results of OperationsMay 13, 2026SC 13DSC 13DMay 5, 2026SC 13D/ASC 13D/AApr 2, 20268-KMaterial Agreement · New Debt / ObligationMar 31, 2026424B5424B5Mar 30, 2026424B5424B5Mar 30, 2026424B5424B5Mar 26, 2026424B5424B5Mar 26, 2026DEFA14ADEFA14AMar 16, 2026DEF 14ADEF 14AMar 16, 202610-K10-KMar 16, 20268-KResults of OperationsMar 16, 20268-KExecutive ChangeFeb 13, 2026SC 13DSC 13DJan 14, 20268-KResults of Operations · Reg FD DisclosureJan 5, 20268-KExecutive ChangeDec 15, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 12, 20258-KReg FD Disclosure · Company UpdateOct 27, 20258-KMaterial Agreement · Results of OperationsOct 8, 20258-KMaterial Agreement · Acquisition / DispositionSep 2, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KExecutive Change · Shareholder VoteJun 12, 20258-KReg FD DisclosureJun 4, 202510-Q10-QMay 15, 20258-KResults of OperationsMay 15, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 202510-K10-KMar 11, 20258-KResults of OperationsFeb 5, 20258-KReg FD DisclosureDec 2, 2024SC 13GSC 13GNov 12, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GNEA 18 VENTURE GROWTH EQUITY, L.P. -- ZENAS BIOPHARMA, INC. 13GSep 25, 2024SC 13DSC 13DSep 23, 2024SC 13DSC 13DSep 23, 2024SC 13DSC 13DSep 23, 20248-KBylaw AmendmentSep 16, 2024424B4424B4Sep 13, 2024S-1/AS-1/ASep 6, 2024S-1S-1Aug 22, 2024
Insider Activity
◆ Cluster Buy · 3 insidersIn the 90 days to Mar 31, 2026: 3 insiders bought $6.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Lu HongboDirector | Buy | 75,000 | $20.00 | $1.5M |
| Mar 31, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 34,000 | $19.31 | $657K |
| Mar 30, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 20,000 | $18.23 | $365K |
| Feb 13, 2026 | Allen Patricia LDirector | Buy | 4,160 | $26.36 | $110K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,700 | $24.34 | $139K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,000 | $26.50 | $133K |
| Feb 12, 2026 | Allen Patricia LDirector | Buy | 5,000 | $23.77 | $119K |
| Feb 11, 2026 | Lu HongboDirector | Buy | 25,985 | $22.50 | $585K |
| Feb 2, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 57,000 | $17.96 | $1.0M |
| Jan 9, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 20,000 | $16.55 | $331K |
| Jan 8, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 30,000 | $16.30 | $489K |
| Jan 7, 2026 | Moulder Leon O JrChief Executive Officer | Buy | 50,000 | $16.38 | $819K |
| Oct 9, 2025 | Enright Patrick GDirector | Buy | 105,265 | $19.00 | $2.0M |
| Oct 9, 2025 | Sr One Capital Management, LlcTenPercentOwner | Buy | 63,158 | $19.00 | $1.2M |
| Oct 9, 2025 | Nunn Jason RaleighDirector | Buy | 63,158 | $19.00 | $1.2M |
| Oct 9, 2025 | Sr One Capital Management, LlcTenPercentOwner | Buy | 63,157 | $19.00 | $1.2M |
| Oct 9, 2025 | Enright Patrick GDirector | Buy | 11,990 | $20.85 | $250K |
| Oct 7, 2025 | Harwin Peter EvanDirector | Buy | 316,219 | $19.00 | $6.0M |
| Oct 7, 2025 | Lu HongboDirector | Buy | 263,160 | $19.00 | $5.0M |
| Oct 7, 2025 | Moulder Leon O JrSee Remarks | Buy | 36,928 | $20.85 | $770K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance